BeOne Medicines Ltd. (ONC)

Market Cap	30.35B
Revenue (ttm)	4.18B
Net Income (ttm)	-394.86M
Shares Out	118.61M
EPS (ttm)	-3.75
PE Ratio	n/a
Forward PE	101.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	393,637
Open	255.22
Previous Close	257.00
Day's Range	250.00 - 257.61
52-Week Range	141.31 - 287.88
Beta	0.30
Analysts	Strong Buy
Price Target	326.43 (+27.58%)
Earnings Date	May 7, 2025

About ONC

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Financial Performance

In 2024, BeOne Medicines's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in CNY

Analyst Forecast

According to 7 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price forecast is $326.43, which is an increase of 27.58% from the latest price.

Price Target

$326.43

(27.58% upside)

Analyst Consensus: Strong Buy